Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This study examined the dementia risk in patients with benign prostatic hyperplasia using alpha-blockers and 5-alpha reductase inhibitors, finding no significant association between these medications and increased dementia risk compared to no treatment, but noted higher risk probabilities for certain 5ARIs.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This review found that adding α1-blockers to 5α-reductase inhibitors may improve lower urinary tract symptoms in men with non-neurogenic conditions, based on existing evidence.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review found that finasteride monotherapy for managing LUTS/BPH significantly reduced prostate volume and improved symptoms, with sexual dysfunctions reported as notable side effects compared to placebo, but emphasizes the need for more comprehensive studies.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

This study found that use of 5-alpha reductase inhibitors for benign prostatic hyperplasia was not associated with an increased risk of hip fracture in men.

This study found that 5alpha-reductase type 1 localizes specifically to sebaceous glands in both normal and acne follicles, suggesting its role in sebum regulation.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.

This study found that the epithelial changes in benign prostatic hyperplasia treated with finasteride resembled the pattern of healthy prostates.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This review discusses the established efficacy and safety of finasteride and dutasteride for benign prostatic hyperplasia, their use with alpha adrenergic blockers, and the potential unclear role in cancer prevention.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This study found that Finnish men using 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had improved disease-specific survival compared to non-users, suggesting potential benefits of the treatment.